TIMP-4 and CD63: New prognostic biomarkers in human astrocytomas

Modern Pathology

Volumn 23, Issue 10, 2010, Pages 1418-1428

  Rorive, Sandrine ^a   Lopez, Xavier Moles ^a,b   Maris, Calliope ^a   Trepant, Anne Laure ^a   Sauvage, Sébastien ^a   Sadeghi, Niloufar ^a   Roland, Isabelle ^a   Decaestecker, Christine ^b   Salmon, Isabelle ^a  

^a ERASME HOSPITAL   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Astrocytoma; CD63; Diagnosis; Image analysis; Immunohistochemistry; Marker; Prognosis; TIMP

Indexed keywords

BIOLOGICAL MARKER; CD63 ANTIGEN; TISSUE INHIBITOR OF METALLOPROTEINASE 4;

ARTICLE; ASTROCYTOMA; CANCER SURVIVAL; CONTROLLED STUDY; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ANTIGENS, CD; ASTROCYTOMA; BRAIN NEOPLASMS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PLATELET MEMBRANE GLYCOPROTEINS; PROGNOSIS; TISSUE ARRAY ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 77957602528     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.136     Document Type: Article

References (36)

1. Giese A, Bjerkvig R, Berens ME, et al. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 2003;21:1624-1636.
2. Louis DN, Ohgaki H, Wiestler OD, et al. The WHO Classification of Tumors of the Central Nervous System, 3rd ed. International Agency for Research on Cancer: Lyon, 2007.
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996.
4. Fernandez C, Figarella-Branger D, Girard N, et al. Pilocytic astrocytomas in children: prognostic factors: a retrospective study of 80 cases. Neurosurgery 2003; 53:544-553.
5. Bondy ML, Scheurer ME, Malmer B, , et al., Brain Tumor Epidemiology Consortium. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer 2008;113:1953-1968.
6. Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009;27:4150-4154.
7. Forshew T, Tatevossian RG, Lawson AR, et al. Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol 2009;218:172-181.
8. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006;24:2707-2714.
9. Rorive S, Maris C, Debeir O, et al. Exploring the distinctive biological characteristics of pilocytic and low-grade diffuse astrocytomas using microarray gene expression profiles. J Neuropathol Exp Neurol 2006; 65:794-807.
10. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002;115:3719-3727.
11. Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002;21:2245-2252.
12. Crocker SJ, Pagenstecher A, Campbell IL. The TIMPs tango with MMPs and more in the central nervous system. J Neurosci Res 2004;75:1-11.
13. Groft LL, Muzik H, Rewcastle NB, et al. Differential expression and localization of TIMP-1 and TIMP-4 in human gliomas. Br J Cancer 2001;85:55-63.
14. Melendez-Zajgla J, Del Pozo L, Ceballos G, et al. Tissue inhibitor of metalloproteinases-4. The road less traveled. Mol Cancer 2008;7:85.
15. Bister V, Skoog T, Virolainen S, et al. Increased expression of matrix metalloproteinases-21 and -26 and TIMP-4 in pancreatic adenocarcinoma. Mod Pathol 2007;20:1128-1140.
16. Lizarraga F, Espinosa M, Maldonado V, et al. Tissue inhibitor of metalloproteinases-4 is expressed in cervical cancer patients. Anticancer Res 2005;25:623-627.
17. Jiang Y, Wang M, Celiker MY, et al. Stimulation of mammary tumorigenesis by systemic tissue inhibitor of matrix metalloproteinase 4 gene delivery. Cancer Res 2001;61:2365-2370.
18. Stetler-Stevenson WG. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal 2008;1:re6.
19. Jung KK, Liu XW, Chirco R, et al. Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J 2006;25:3934-3942.
20. Qi JH, Ebrahem Q, Moore N, et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 2003;9:407-415.
21. Seo DW, Li H, Guedez L, et al. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 2003;114:171-180.
22. Chirco R, Liu XW, Jung KK, et al. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 2006; 25:99-113.
23. Pols MS, Klumperman J. Trafficking and function of the tetraspanin CD63. Exp Cell Res 2009;315:1584-1589.
24. Decaestecker C, Moles Lopez X, DHaene N, et al. Requirements for the valid quantification of immunostains on tissue microarray materials using image analysis. Proteomics 2009;9:4478-4494.
25. Rorive S, Berton A, DHaene N, et al. Matrix metalloproteinase-interplays with the IGFBP2-IGFII complex to promote cell growth and motility in astrocytomas. Glia 2008;56:1679-1690.
26. DHaene N, Maris C, Sandras F, et al. The differential expression of Galectin-1 and Galectin-3 in normal lymphoid tissue and non-Hodgkins and Hodgkins lymphomas. Int J Immunopathol Pharmacol 2005;18:431-443.
27. Gamboa-Dominguez A, Dominguez-Fonseca C, Quintanilla- Martinez L, et al. Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized immunohistochemical detection system. Mod Pathol 2004; 17:579-587.
28. Flynn JR, Wang L, Gillespie DL, et al. Hypoxiaregulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme. Cancer 2008;113: 1032-1042.
29. Shirahata M, Iwao-Koizumi K, Saito S, et al. Gene expression-based molecular diagnostic system for malignant gliomas is superior to histological diagnosis. Clin Cancer Res 2007;13:7341-7356.
30. Giannini C, Scheithauer BW. Classification and grading of low-grade astrocytic tumors in children. Brain Pathol 1997;7:785-798.
31. Tihan T, Fisher PG, Kepner JL, et al. Pediatric astrocytomas with monomorphous pilomyxoid features and a less favorable outcome. J Neuropathol Exp Neurol 1999;58:1061-1068.
32. Hotta H, Ross AH, Huebner K, et al. Molecular cloning and characterization of an antigen associated with early stages of melanoma tumor progression. Cancer Res 1998;48:2955-2962.
33. Wang M, Liu YE, Greene J, et al. Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. Oncogene 1997;14:2767-2774.
34. Iida J, Skubitz AP, McCarthy JB, et al. Protein kinase activity is associated with CD63 in melanoma cells. J Transl Med 2005;3:42.
35. Milano V, Piao Y, LaFortune T, et al. Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma. Mol Cancer Ther 2009;8:394-406.
36. Gleixner KV, Mayerhofer M, Sonneck K, et al. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica 2007;92:1451-1459.